T. Rowe Price Associates’s Kura Oncology KURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $229K | Buy |
39,573
+7,855
| +25% | +$45.5K | ﹤0.01% | 2656 |
|
|
2025
Q1 | $210K | Buy |
31,718
+3,648
| +13% | +$24.2K | ﹤0.01% | 2609 |
|
|
2024
Q4 | $245K | Buy |
28,070
+4,344
| +18% | +$37.9K | ﹤0.01% | 2594 |
|
|
2024
Q3 | $464K | Buy |
23,726
+672
| +3% | +$13.1K | ﹤0.01% | 2279 |
|
|
2024
Q2 | $475K | Buy |
23,054
+2,906
| +14% | +$59.9K | ﹤0.01% | 2207 |
|
|
2024
Q1 | $430K | Buy |
20,148
+2,940
| +17% | +$62.7K | ﹤0.01% | 2270 |
|
|
2023
Q4 | $248K | Sell |
17,208
-17,659
| -51% | -$255K | ﹤0.01% | 2453 |
|
|
2023
Q3 | $318K | Buy |
34,867
+10,499
| +43% | +$95.8K | ﹤0.01% | 2306 |
|
|
2023
Q2 | $258K | Buy |
24,368
+608
| +3% | +$6.44K | ﹤0.01% | 2431 |
|
|
2023
Q1 | $291K | Buy |
23,760
+975
| +4% | +$11.9K | ﹤0.01% | 2355 |
|
|
2022
Q4 | $283K | Sell |
22,785
-3,963
| -15% | -$49.2K | ﹤0.01% | 2394 |
|
|
2022
Q3 | $366K | Sell |
26,748
-11,048
| -29% | -$151K | ﹤0.01% | 2281 |
|
|
2022
Q2 | $693K | Buy |
37,796
+423
| +1% | +$7.76K | ﹤0.01% | 2063 |
|
|
2022
Q1 | $601K | Buy |
37,373
+15,296
| +69% | +$246K | ﹤0.01% | 2251 |
|
|
2021
Q4 | $309K | Sell |
22,077
-17,278
| -44% | -$242K | ﹤0.01% | 2585 |
|
|
2021
Q3 | $737K | Buy |
39,355
+6,336
| +19% | +$119K | ﹤0.01% | 2189 |
|
|
2021
Q2 | $688K | Buy |
33,019
+1,273
| +4% | +$26.5K | ﹤0.01% | 2226 |
|
|
2021
Q1 | $897K | Buy |
31,746
+7,924
| +33% | +$224K | ﹤0.01% | 2105 |
|
|
2020
Q4 | $778K | Buy |
23,822
+2,926
| +14% | +$95.6K | ﹤0.01% | 2046 |
|
|
2020
Q3 | $640K | Buy |
+20,896
| New | +$640K | ﹤0.01% | 1988 |
|